After the 2021 A level exam results were announced, the RSS made a statement outlining priorities for next steps. Read the news story here.

Professors Sylvia Richardson and Sir David Spiegelhalter, who co-chair the RSS Covid-19 Task Force, wrote a piece on how we might learn from decision theory when deciding next steps in the Covid-19 pandemic.

A 95-page report with recommendations around study design, regulation and transparency matters with regard to in vitro diagnostic tests.

By RSS President, Sylvia Richardson

Letter from Sylvia Richardson and Jon Deeks to the Guardian on the need for more evidence on lateral flow tests.

From Sylvia Richardson, Deborah Ashby and Jon Deeks

Statement on the need for transparency about secondary pupils’ uptake of Lateral Flow Testing, PCR-corroboration, cycle-threshold-values (proxy for viral load) & genomic analyses

RSS welcomes the publication of OSR's review of the use of models for awarding grades in the UK in 2020 (2 March)

Letter from Stian Westlake to The Times on why the government needs to re-evaluate its schools coronavirus testing strategy.

Written by Jon Deeks on behalf of the Working Group on Diagnostic Tests.

to the joint Health and Social Care Committee and Science and Technology Committee Inquiry: ‘Coronavirus: Lessons Learnt'

Written evidence from the Royal Statistical Society (DTA 42) for the Public Administration and Constitutional Affairs Committee inquiry on Data Transparency and Accountability: Covid 19.

We focus on Question 4, 'How the Coroners Service has dealt with Covid-19', since it links most closely to the Society’s work on official statistics and our longstanding concerns around death registration.

Making the case for a review of the models and processes adopted by the UK qualifications regulators.

With accompanying technical appendix.

RSS Response to the Education Select Committee call for evidence: The Impact of Covid-19 on education and children's services inquiry

From the RSS International Development Section

Responding to the criteria that the Medicines and Healthcare Products Regulatory Authority (MHRA) expects to be met by an acceptable point-of-care antibody test for coronavirus

From David Spiegelhalter to the Medicines and Healthcare Regulatory Authority on behalf of the RSS Task Force